Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in Japan
- PMID: 34730287
- PMCID: PMC8818832
- DOI: 10.1111/irv.12928
Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in Japan
Abstract
Background: The frequency and clinical profile of respiratory syncytial virus (RSV)-acute respiratory disease (ARD) in older adults in Japan has not been well-characterized.
Methods: This was a multicenter prospective observational cohort study to evaluate the occurrence rate of ARD in 1000 older adult participants (≥65 years) for 52 weeks during the 2019 to 2020 season. A multiplex polymerase chain reaction panel was used for pathogen detection in nasopharyngeal swab from participants diagnosed with ARD. Symptoms and impact of ARD was assessed using the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™). The study was registered at UMIN (https://www.umin.ac.jp/ctr/): UMIN000037891.
Results: RSV-ARD was detected in 24/1000 (2.4%) participants and RSV-lower respiratory tract disease in 8/1000 (0.8%) participants. The median duration of RSV-ARD was 18 days. All 24 participants had utilized the medical services of outpatient visits and only 1 (4.2%) participant was hospitalized for RSV-ARD. The most common viruses other than RSV that caused ARD (detected in >10 participants) were human rhinovirus/enterovirus, parainfluenza 3, coronavirus OC43, human metapneumovirus, and influenza A/H1. The most frequent symptoms of RSV-ARD were cough, sore throat, nasal congestion, and expectoration.
Conclusions: RSV was reported as a major pathogen for respiratory infections in older adults in Japan.
Keywords: Japanese older adults; acute respiratory disease; community; respiratory infection intensity questionnaire (RiiQ™); respiratory pathogens; respiratory syncytial virus.
© 2021 Janssen Pharmaceutical K.K. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Conflict of interest statement
Potential conflict of interest: NM, YM, ZR, and SY are full time employees and KD had been a consultant of Janssen Pharmaceutical K.K., Tokyo, Japan. NM and YM are J&J stockholders.
No conflict of interest: TH reports no conflicts of interest in this work.
Figures
References
-
- Centers for Disease Control and Prevention . Respiratory syncytial virus infection (RSV). Available at: https://www.cdc.gov/rsv/index.html. Accessed 08 April 2021.
-
- Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus‐associated acute respiratory infection in older adults in 2015: a systematic review and meta‐analysis. J Infect Dis. 2020;222(supplement_7:S577‐S583. - PubMed
-
- Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high‐risk adults. N Engl J Med. 2005;352(17):1749‐1759. - PubMed
-
- Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus infection in community‐dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
